

HOFFMAN, WASSON & GITLER, PC (703) 415-0100

Docket No. : 57109(71699) 03-1438
 Inventor/Applicant : S. Denmeade et al.
 Serial/Patent No. : 09/627,600
 Filing/Issue Date : July 28, 2000
 Title : Activation of Peptide
 Prodrugs by (HK2)

RECEIVED
 TECH CENTER 1600/2300
 03 MAY 27 PM 5:16

The U.S. Patent and Trademark Office acknowledges receipt of:

PATENTS

- ☒ Transmittal Letter (1 pgs)
- ☐ Patent Application
 - Specification (pgs), Claims (pgs) & Abstract (pgs)
 - Drawings - sheets (formal/ informal)
 - Declaration/Power of Attorney (signed/ unsigned) (1 pgs)
 - Certificate Under Section 3.73(b) (pgs)
 - Preliminary Amendment (pgs)
 - Assignment w/ Transmittal (pgs)
 - Priority Document(s) (certified/ uncertified)
 - IDS/PTO Form 1449 (pgs) w/ References (Documents)
 - Issue Fee w/ Transmittal
 - Maintenance Fee w/ Transmittal (w/ Surcharge/ w/o Surcharge)
 - Amendment/Response/Communication (pgs)
 - Marked-Up Claims (pgs) (Substitute Sheet(s) of Claims (pgs)
 - Extension of Time (pgs)
 - Terminal Disclaimer (pgs)
 - PCT Request Form (pgs)
 - Fee Calculation Sheet (pgs)
 - National Phase 371 Transmittal (pgs)
 - Demand for Preliminary Examination (Chapter II) (pgs)
 - Response to Written Opinion (pgs)
 - Copy of International Application, as filed (PCT/ /)
 - Specification (pgs), Claims (pgs) & Abstract (pgs)
 - Copy of Published International Application (WO)
 - Specification (pgs), Claims (pgs) & Abstract (pgs)
 - Copy of International Search Report (pgs)
 - Translation of Priority Application No. , filed (certified/ uncertified) (pgs)
 - Petition (pgs)

MISCELLANEOUS

☒ Supplemental Response to Notice 2 pages
 11 to comply
 Copy of Response filed 7-18-2002 49 pages
 Copy of Receipt Card
 Copy of Falsimile 5 pages

CHECK NO. IN THE AMOUNT OF \$
 CHECK NO. IN THE AMOUNT OF \$
 DEPOSIT ACCOUNT TRANSACTION \$

File: Group 1653 Examiner S. Liu

Express Mail Label No. EL 933049160 US
Attorney Docket No. 57109 (71699)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S)	S. Denmeade, et al.	EXAMINER:	S. Liu
U.S.S.N.:	09/627,600	GROUP:	1653
FILED (U.S.):	July 28, 2000	Conf. No.	3631
FOR:	ACTIVATION OF PEPTIDE PRODRUGS BY (HK2)		

BOX SEQUENCE
Commissioner for Patents
Washington, D.C. 20231

Sir/Madam:

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES**

The following is in response to the Notice to Comply with Requirements for
Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence
Disclosures, mailed July 3, 2002, in the above-referenced application.

Enclosed herewith for filing in the subject application are the following:

1. Paper Copy of Sequence Listing previously submitted;
2. New Computer Readable Form (CRF) of Sequence Listing;
3. Copy of Notice To Comply With Requirements For Patent Applications
Containing Nucleotide Sequence And/Or Amino Acids Sequence Disclosures;
4. Copy of Error Report indicating unreadable disc;
5. Amendment directing entry of Paper Copy of Sequence Listing into specification
[included in this paper];
6. Statement Accompanying Submission Of Sequence Listing Under 37 C.F.R. §
1.821(g) [included in this paper];
7. Associate Power of Attorney; and
8. Change of Correspondence Address.

Attorney Docket No. 57109 (71699)
U.S.S.N. 09/627,600
Filed (U.S.): July 28, 2000
Page 2 of 2

AMENDMENT DIRECTING ENTRY OF SEQUENCE LISTING

At the last page of the specification, please enter the attached paper copy of the Sequence Listing (25 pages) and number the pages as appropriate.

STATEMENT ACCOMPANYING SUBMISSION OF SEQUENCE LISTING

Provided herewith is a Paper Copy of a Sequence Listing for the nucleotide and/or amino acid sequence(s) in this application. Each Sequence has been assigned a separate identifier as required in 37 C.F.R. § 1.821(c) and 37 C.F.R. §§ 1.822 and 1.823. An amendment directing entry of the Paper Copy of the Sequence Listing into the specification is provided above.

Applicants further provide a Computer Readable Form (CRF) corresponding to the Paper Copy of the Sequence Listing provided herewith. Pursuant to 37 C.F.R. § 1.821(g), Applicants' agent hereby states that the CRF corresponds exactly to the Paper Copy of the Sequence Listing provided herewith. Applicants' agent further hereby states that the contents of the Paper Copy of the Sequence Listing and CRF do not go beyond the disclosure in the Application as filed and do not introduce new matter.

If for any reason, the fee paid is inadequate or credit is owed for any excess fee paid, you are hereby authorized and requested to charge Deposit Account No. 04-1105.

Date:

July 18, 2002

Respectfully submitted,

Dianne M. Rees
Dianne M. Rees, Ph.D.
(Reg. No. 45,281)
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, MA 02209

Telephone: 617-439-4444
Customer No. 21874
BOS2_907161.1